Eye Practice and Physician Owner Agree to Pay $415,000 to Resolve Allegations of False Claims Act to Medicare

Why It Matters

The case highlights growing federal scrutiny of referral kickbacks and false Medicare billing, signaling heightened compliance risk for specialty clinics.

Key Takeaways

• Mitchell Eye Center pays $415,000 to settle False Claims Act allegations
• False Medicare claims involved non‑necessary transcranial doppler tests
• Payments tied to referrals violated anti‑kickback statutes
• Physicians falsified vertebro‑basilar insufficiency diagnoses for billing
• Settlement underscores heightened DOJ scrutiny of ophthalmology referrals

Pulse Analysis

The Department of Justice’s $415,000 settlement with the Mitchell Eye Center underscores how the False Claims Act continues to be a powerful tool against improper Medicare billing. The case centers on transcranial doppler (TCD) tests—diagnostic procedures that were billed to Medicare and the Veterans Health Administration despite lacking medical necessity. By linking referral fees to each test, the practice and its partner, Eyecuity, breached the anti‑kickback statute, while physicians signed off on rare vertebro‑basilar insufficiency diagnoses they did not substantiate. This combination of overbilling and falsified clinical documentation triggered a coordinated investigation involving the U.S. Attorney’s Office and the VA Office of Inspector General.

For ophthalmology and other specialty practices, the settlement serves as a cautionary tale about the perils of fee‑for‑referral arrangements. Contracts that compensate providers based on the volume of tests or procedures, rather than fair market value for legitimate services, can quickly cross into illegal territory. Compliance programs must rigorously audit billing practices, ensure that clinical documentation reflects true patient conditions, and train staff on the nuances of the Anti‑Kickback Statute. The financial penalty, though modest relative to larger health‑care fraud cases, illustrates that even mid‑size clinics are not immune to federal enforcement.

The broader regulatory climate suggests that the DOJ and HHS Office of Inspector General will intensify oversight of specialty referrals, especially in high‑reimbursement domains like imaging and diagnostics. Industry observers anticipate more whistle‑blower actions and settlements as agencies leverage data analytics to spot patterns of unnecessary testing. Practices that proactively adopt transparent referral policies and robust internal controls can mitigate risk and preserve reputational capital in an environment where compliance is increasingly tied to financial performance.